Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo
- PMID: 1950544
- DOI: 10.3109/00016489109138414
Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo
Abstract
In a previous report we have characterized cisplatin (CDDP)-resistant sublines (HLac 79-DDP1 to DDP4) of the recloned squamous cell head and neck cancer (SCHNC) line HLac 79-ML revealing significant alterations of glutathione (GSH) metabolism and drug accumulation. In order to overcome CDDP-resistance in HLac 79 cells we now investigated the effect of buthionine sulfoximine (BSO), a specific inhibitor of GSH synthesis, verapamil (VRP), a calcium channel blocker that has been found to modulate resistance towards a broad spectrum of antineoplastic drugs, cyclosporin A (CSA), an immunosuppressive agent probably affecting drug pharmacokinetics, and aphidicolin (APC), a fungal metabolite interfering with DNA repair through inhibition of DNA polymerase alpha, on HLac 79 CDDP-sensitivity. Using the colorimetric MTT assay, GSH depletion with BSO led to a significant decrease of the 50% inhibitory drug concentration (IC50) in all HLac 79 sublines by dose modifying factors (IC50 CDDP/IC50 BSO + CDDP) ranging from 1.8 to 3.3. VRP, CSA or APC were not effective to overcome CDDP resistance in HLac 79 cells. The potential of BSO to modulate CDDP resistance in vitro was tested in vivo in HLac 79 tumor bearing NMRI nu-nu mice subsequently. Oral administration of BSO 7 days prior and during (days -7 to 8) CDDP treatment (3 mg/kg bw i.p. days 0, 4, 8) produced a significant prolongation of mean survival time mean as compared to chemotherapy alone. This held true for both the maternal line ML in terms of chemosensitization (CDDP: mean = 40.2 +/- 15.9 days vs. CDDP + BSO: mean = 80.3 +/- 30.4 days, p less than 0.001) and the CDDP resistant subline DDP4 in terms of partially overcoming secondary drug resistance (CDDP: mean = 56.5 +/- 13.6 days vs. CDDP + BSO: mean = 72.5 +/- 15.8 days, p less than 0.001). Enhanced toxicity of combined BSO and CDDP treatment manifested by transient 10% reduction of animal mean body weight.
Similar articles
-
[Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].Laryngorhinootologie. 1990 Jan;69(1):16-20. doi: 10.1055/s-2007-998133. Laryngorhinootologie. 1990. PMID: 2310456 German.
-
Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79.Acta Otolaryngol. 1990 Nov-Dec;110(5-6):466-73. doi: 10.3109/00016489009107470. Acta Otolaryngol. 1990. PMID: 2284922
-
Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.Int J Cancer. 1993 Nov 11;55(5):848-56. doi: 10.1002/ijc.2910550526. Int J Cancer. 1993. PMID: 8244583
-
Resistance to cisplatin and analogues: mechanisms and potential clinical implications.Cancer Chemother Pharmacol. 1988;22(4):325-32. doi: 10.1007/BF00254240. Cancer Chemother Pharmacol. 1988. PMID: 3048763 Review.
-
Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.Pharmacol Ther. 1990;48(1):19-27. doi: 10.1016/0163-7258(90)90015-t. Pharmacol Ther. 1990. PMID: 2274575 Review.
Cited by
-
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer.J Bioenerg Biomembr. 2007 Feb;39(1):43-50. doi: 10.1007/s10863-006-9059-5. J Bioenerg Biomembr. 2007. PMID: 17318397 Review.
-
Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion.J Cancer Res Clin Oncol. 1996;122(11):653-8. doi: 10.1007/BF01209027. J Cancer Res Clin Oncol. 1996. PMID: 8898974 Free PMC article.
-
Chemotherapeutic drug resistance in the management of head and neck cancer.Eur Arch Otorhinolaryngol. 1993;250(4):200-8. doi: 10.1007/BF00171524. Eur Arch Otorhinolaryngol. 1993. PMID: 8369114 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials